Associated Papers
Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.
Middha S et al.
Jco Precision Oncology, 2019
Select a paper to view details